Posted May. 22, 2012 at 12:34 p.m.

Premium Lock Charlotte-based Chelsea retargets new drug application for 2013

Published: 2012-05-22 12:34:05
Updated: 2012-05-22 12:34:05

Chelsea Chelsea

The therapeutics firm announced the plans following its meeting with the U.S. Food and Drug Administration to discuss the complete response letter received for Northera, a compound developed to treat dizziness and fainting in Parkinson's disease patients....

Read More
Read More

WRAL TechWire any time: Twitter, Facebook

Copyright 2017 MedCity. All rights reserved.
Editor's Blog

Editor's Blog

The latest blog posts from our WRAL TechWire and WRAL editors. Read more articles…

Please Log In to add a comment.

Latest for Insiders